TherapeuticsMD Files 8-K on Shareholder Nominations
Ticker: TXMD · Form: 8-K · Filed: Sep 20, 2024 · CIK: 25743
Sentiment: neutral
Topics: governance, shareholder-nomination
Related Tickers: TXMD
TL;DR
TXMD filed an 8-K about shareholder nominations - could mean board shakeup.
AI Summary
On September 20, 2024, TherapeuticsMD, Inc. filed an 8-K report detailing shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing does not contain specific financial figures or new business developments beyond the procedural notification.
Why It Matters
This filing indicates potential changes or activism from shareholders regarding the company's board or governance, which could impact future strategic decisions.
Risk Assessment
Risk Level: medium — Shareholder nominations can signal dissatisfaction or a push for change, introducing uncertainty about the company's future direction and leadership.
Key Players & Entities
- TherapeuticsMD, Inc. (company) — Registrant
- Exchange Act Rule 14a-11 (legal_document) — Governing rule for shareholder nominations
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report shareholder nominations pursuant to Exchange Act Rule 14a-11.
What is the exact name of the company filing this report?
The exact name of the company is TherapeuticsMD, Inc.
On what date was this report filed?
The report was filed on September 20, 2024.
In which state was TherapeuticsMD, Inc. incorporated?
TherapeuticsMD, Inc. was incorporated in Nevada.
What is the principal executive office address for TherapeuticsMD, Inc.?
The principal executive office is located at 951 Yamato Road, Suite 220, Boca Raton, FL 33431.
Filing Stats: 739 words · 3 min read · ~2 pages · Grade level 15.8 · Accepted 2024-09-20 17:00:30
Key Financial Figures
- $0.001 — ch Registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Mar
Filing Documents
- ea0215273-8k_therap.htm (8-K) — 24KB
- 0001213900-24-080719.txt ( ) — 198KB
- txmd-20240920.xsd (EX-101.SCH) — 3KB
- txmd-20240920_lab.xml (EX-101.LAB) — 34KB
- txmd-20240920_pre.xml (EX-101.PRE) — 22KB
- ea0215273-8k_therap_htm.xml (XML) — 4KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations. TherapeuticsMD, Inc., a Nevada corporation (the "Company"), will hold its 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting") on Thursday, December 5, 2024. Holders of record of the Company's common stock outstanding as of the close of business on Thursday, October 17, 2024, will be entitled to notice of, and to vote at, the 2024 Annual Meeting. The time, place and detailed information regarding the proposals to be presented at the 2024 Annual Meeting will be as set forth in the Company's definitive proxy statement for the 2024 Annual Meeting to be filed with the Securities and Exchange Commission (the "SEC"). Because the scheduled date of the 2024 Annual Meeting is more than thirty (30) days after the anniversary of the Company's 2023 annual meeting of stockholders, prior disclosed deadlines regarding the submission of stockholder proposals for the 2024 Annual Meeting are no longer applicable. The Company is hereby providing notice of certain revised deadlines for the submission of stockholder proposals in connection with the 2024 Annual Meeting. Stockholders who intend to present proposals for inclusion in the Company's proxy materials for the 2024 Annual Meeting pursuant to Rule 14a-8 ( "Rule 14a-8") promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), must ensure that such proposals are received by the Company, in writing, at 951 Yamato Road, Suite 220, Boca Raton, FL 33431, and be directed to the attention of the Corporate Secretary, no later than September 30, 2024, which the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials for the 2024 Annual Meeting, and must furthermore comply with all applicable SEC rules, including the applicable requirements of Rule 14a-8. To be considered timely, stockholders who intend to present proposals for director nominations or any other proposal at the 2024 Annual Meeting